Evidence map›Paper›PMID 39119802›Full record

ArticleCancer medicine2024

Impact of intra-tumoral immunity on predicting response and survival after neoadjuvant cisplatin-based chemotherapy in patients with muscle invasive bladder cancer.

Alberto Mendoza-Valderrey, Jane Choe, Daria M Kessler, Gianna Jimenez, Xinmin Li, Steven Kolker, Warren Allen, Jennifer A Linehan, Przemyslaw W Twardowski, Maria Libera Ascierto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. The promising arsenal of ferroptosis inducers in bladder cancer.Journal of molecular medicine (Berlin, Germany) · 2025
    Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alberto Mendoza-ValderreyTranslational Cancer Immunology and Immunotherapy Department, Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, California, USA.ORCID 0000-0003-4849-1593
Jane ChoeDepartment of Urologic Oncology, Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, California, USA.
Daria M KesslerBioinformatic Department, Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, California, USA.
Gianna JimenezDepartment of Urologic Oncology, Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, California, USA.
Xinmin LiTechnology Center for Genomics and Bioinformatics, UCLA, Los Angeles, California, USA.
Steven KolkerPathology Department, Providence Saint John's Health Center, Santa Monica, California, USA.
Warren AllenPathology Department, Providence Saint John's Health Center, Santa Monica, California, USA.
Jennifer A LinehanDepartment of Urologic Oncology, Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, California, USA.
Przemyslaw W TwardowskiDepartment of Urologic Oncology, Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, California, USA.
Maria Libera AsciertoTranslational Cancer Immunology and Immunotherapy Department, Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, California, USA.ORCID 0009-0008-8904-1613

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
NCI NIH HHS P30 CA016042Rosalie and Harold Rae Brown Foundation
6 · The paper itself

Abstract

backgroundNeoadjuvant cisplatin-based chemotherapy (NAC) followed by cystectomy is the standard of care for patients with muscle-invasive bladder cancer (MIBC). Pathologic complete response (pCR) is associated with favorable outcomes, but only 30%-40% of patients achieve that response. The aim of this study is to investigate the role played by the Tumor and Immune Microenvironment (TIME) in association with the clinical outcome of patients with MIBC undergoing NAC.

methodsNineteen patients received NAC and were classified as pCR (n = 10) or non-pCR (n = 9). Bulk RNA-seq and immune protein evaluations using Digital Spatial Profiling (DSP) were performed on formalin-fixed paraffin-embedded (FFPE) tumor biopsies collected before NAC (baseline). Immunohistochemistry (IHC) evaluation focused on CD3 and CD20 expression was performed on baseline and end-of-treatment (EOT) FFPEs. Baseline peripheral blood was assessed for lymphocyte and neutrophil counts. Kaplan-Meier analyses and Cox PH regression models were used for survival analyses (OS).

resultsIn the periphery, pCR patients showed lower neutrophil counts, and neutrophil/ lymphocyte ratio (NLR) when compared to non-pCR patients. In the tumor microenvironment (TME), gene expression analysis and protein evaluations highlighted an abundance of B cells and CD3

conclusionsIn the current study, we demonstrated that lower NLR levels and increased CD3

Indexed as

CisplatinNeoadjuvant TherapyTumor MicroenvironmentUrinary Bladder NeoplasmsAgedAntineoplastic Combined Chemotherapy ProtocolsCystectomyFemaleHumansMaleMiddle AgedNeoplasm InvasivenessNeutrophilsPrognosisTreatment OutcomeCisplatinbiomarkersbladder cancerdigital pathologyneoadjuvant

Identifiers

PMID39119802
PMCPMC11310761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.